文献速递关节外科运动医学

第一代自体软骨细胞移植术后20年随访

A 20-Year Follow-up After First-Generation Autologous Chondrocyte Implantation.
PubMed 文献 · Am J Sports Med · 2017-07-26

该病例系列对23例患者(24膝)因致残性大面积软骨缺损接受第一代自体软骨细胞移植(ACI)的患者进行至少20年随访。20年生存率为63%(95%CI,40%-78%),15膝移植物保留者除WOMAC僵硬子评分和SF-36心理成分摘要评分外,其余临床评分均显著改善并维持至术后20年。93%的患者自评膝关节特异性结局为良好或优秀,79%的患者维持了自身膝关节并对评估满意。

要点

  • 第一代ACI术后20年生存率为63%(95%CI,40%-78%),79%患者维持自身膝关节并满意。
  • 15膝移植物保留者中,除WOMAC僵硬子评分和SF-36心理成分摘要评分外,其余临床评分均显著改善并维持至20年。
  • 24膝中9膝失败,其中5膝行翻修ACI、4膝转为关节置换,平均时间分别为1.7年和5.9年。

核心结论

  • 第一代ACI在20年随访中提供了满意的生存率和显著的临床改善,为未来新一代ACI技术比较提供了重要标准。

研究设计与样本

  • 病例系列研究,证据等级4级;前瞻性收集23例患者(24膝)数据,平均年龄35.4岁(范围13-52岁),平均每膝治疗2.1处病变,平均总表面积11.8 cm²(范围2.4-30.5 cm²)。

主要发现

  • 20年生存率为63%(95%CI,40%-78%)。
  • 15膝移植物保留者中,除WOMAC僵硬子评分和SF-36心理成分摘要评分外,所有临床评分均显著改善并维持至术后20年。
  • 上述患者中93%自评膝关节特异性结局为良好或优秀。
  • 24膝中9膝失败,包括5膝行翻修ACI(平均1.7年)和4膝转为关节置换(平均5.9年)。
  • 5膝行翻修ACI中仅1膝在指数手术后1.9年转为关节置换,其余4例患者得以维持生物膝关节;20年后79%的患者维持了最初寻求治疗的自身膝关节并对评估满意。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treating articular cartilage defects is a demanding problem. Although several studies have reported durable and improved clinical outcomes after autologous chondrocyte implantation (ACI) over a long-term period, there is no report with over 20 years' follow-up. PURPOSE: To evaluate clinical outcomes after first-generation ACI for the treatment of knees with disabling, large single and multiple cartilage defects for which patients wished to avoid prosthetic arthroplasty, with a minimum of 20 years' follow-up. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: The authors reviewed prospectively collected data from 23 patients (24 knees; mean age, 35.4 years [range, 13-52 years]) undergoing ACI for the treatment of symptomatic, full-thickness articular cartilage lesions. A mean of 2.1 lesions per knee were treated over a mean total surface area of 11.8 cm2 (range, 2.4-30.5 cm2) per knee. Kaplan-Meier survival analysis and functional outcome scores, including the modified Cincinnati Knee Rating System, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Short Form-36 (SF-36), were used. Patients also self-reported an improvement in pain with a visual analog scale and a satisfaction survey. RESULTS: The 20-year survival rate was 63% (95% CI, 40%-78%). The evaluation of the 15 knees with retained grafts demonstrated that all clinical scores except the WOMAC subscore for stiffness and SF-36 mental component summary score improved significantly and were sustained to 20 years postoperatively. Ninety-three percent of these patients rated knee-specific outcomes as good or excellent. The outcomes for 9 of 24 knees were considered failures, including 5 undergoing revision ACI and 4 being converted to arthroplasty at a mean of 1.7 and 5.9 years, respectively. Only 1 of 5 knees that underwent revision ACI was converted to arthroplasty at 1.9 years after the index surgery, and the other 4 patients were able to maintain their biological knee. Overall, 20 years later, 79% of patients maintained their native knee, for which they initially sought treatment, and were satisfied when evaluated. CONCLUSION: First-generation ACI provided satisfactory survival rates and significant clinical improvements over a 20-year follow-up, which offers an important standard for comparison with newer-generation ACI technologies of the future.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Ogura T, Mosier BA, Bryant T, et al. A 20-Year Follow-up After First-Generation Autologous Chondrocyte Implantation. Am J Sports Med. 2017. PMID: 28745972. doi:10.1177/0363546517716631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。